Introduction
============

Apolipoprotein E-mediated transport of cholesterol from astrocytes to neurons is crucial for the maintenance of synaptic connections and neuronal membranes ([@awy289-B59]; [@awy289-B28]). There are three major alleles of the apolipoprotein E (*APOE*) gene that codes for apolipoprotein E in humans---ɛ2, ɛ3, and ɛ4 (*APOE2*, *APOE3*, and *APOE4*, respectively)---with an approximate worldwide distribution of 7%, 79%, and 14%, respectively ([@awy289-B6]). Expression of *APOE4* has profound consequences within the brain, including greatly increased Alzheimer\'s disease risk as well as neurological effects that are independent of the hallmark Alzheimer\'s disease pathologies of amyloid-β plaques or neurofibrillary tangles ([@awy289-B28]; [@awy289-B51]). In the absence of a dementia diagnosis, human *APOE4* carriers may still display cognitive decline and olfactory identification impairments compared to age-matched non-carriers ([@awy289-B40]; [@awy289-B57]). Brain imaging studies also reveal *APOE4*-driven structural and functional differences within regions of the hippocampus and cortex at ages before *APOE4*-mediated Alzheimer\'s disease would be expected ([@awy289-B7]; [@awy289-B16]; [@awy289-B50]; [@awy289-B14]), with some studies ruling out amyloid-β burden as a contributing factor ([@awy289-B50]). The idea that *APOE4* expression has deleterious effects on the brain outside of its impact on hallmark Alzheimer\'s disease pathologies is further supported by studies using humanized *APOE* mouse models that do not develop amyloid-β plaques or neurofibrillary tangles ([@awy289-B54]; [@awy289-B55]). *APOE4* mice show memory impairments in the Morris water maze ([@awy289-B4]), which have been suggested to result from regional cell loss ([@awy289-B56]). Moreover, we have recently linked olfactory memory impairments in *APOE4* mice to network abnormalities in olfactory brain regions ([@awy289-B42]). While the mechanisms by which *APOE4* genotype compromises neuronal viability and function are likely to be multifactorial, recent studies show that a main mechanism may be the *APOE4*-driven dysfunction of the neuronal endosomal-lysosomal system ([@awy289-B39]; [@awy289-B58]).

Apolipoprotein E-transported cholesterol is made available to neurons upon release into early endosomes after receptor-mediated internalization, where the cholesterol is then delivered to late endosomes/multivesicular bodies ([@awy289-B23]). Within multivesicular bodies, intraluminal vesicles are generated in a process that is mediated by the endosomal sorting complexes required for transport (ESCRT) machinery, which includes the tumor susceptibility 101 (TSG101) gene subunit and its associated protein apoptosis-linked gene 2-interacting protein X (ALIX; encoded by *PDCD6IP*) ([@awy289-B45]). Intraluminal vesicles are either degraded in lysosomes or released to the extracellular space as exosomes, which requires the function of small Rab-GTPases such as Rab35 for the fusion of intraluminal vesicle-containing multivesicular bodies with the cell plasma membrane ([@awy289-B22]; [@awy289-B41]). Exosomes play diverse physiological roles in the brain, contributing to both synaptic plasticity and neuronal survival ([@awy289-B46]; [@awy289-B27]). In addition to the beneficial cell-to-cell delivery of RNA, proteins, and lipids ([@awy289-B46]; [@awy289-B27]), exosomes may also contribute to the cell-to-cell and cell-to-extracellular space spread of pathogenic proteins ([@awy289-B27]). Importantly, exosome secretion offers a mechanism, in addition to lysosomal degradation, for the removal of intracellular materials from the endosomal system ([@awy289-B27]). Given that *APOE4* genotype is linked to neuronal endosome morphological alterations in human Alzheimer\'s disease brains ([@awy289-B8]), that *APOE4* genotype in mouse models is sufficient to alter early endosomes and lysosomes ([@awy289-B39]; [@awy289-B58]), and that cholesterol has been implicated in intraluminal vesicle biogenesis ([@awy289-B53]), we sought to determine whether exosome production from the endosomal pathway is disrupted by *APOE4*.

We demonstrate *APOE4*-driven decreases in exosome levels in the post-mortem brains of neuropathologically healthy humans as well as in an age-dependent manner in *APOE* mice. We further reveal differences in the levels of key exosomal-pathway regulatory proteins as well as of brain-exosome lipids, demonstrating that *APOE4* compromises brain exosome production in a manner that may be linked to *APOE4*-mediated changes in cholesterol levels. Alongside recent reports from our group ([@awy289-B39]) and others ([@awy289-B58]), the present findings demonstrate that *APOE4* genotype disrupts exosome production in the context of broad neuronal endosomal-lysosomal pathway alterations. We propose that exosomal pathway dysfunction is an integral component of *APOE4*-driven endosomal-lysosomal pathway alterations that are likely to contribute to ageing-dependent neuron vulnerability, cognitive impairment, and Alzheimer\'s disease risk.

Materials and methods
=====================

Animals
-------

All experimental procedures involving animals were approved by and complied with the guidelines of the Institutional Animal Care and Use Committee of the Nathan S. Kline Institute. The mice used in this study were from our longstanding colonies. *APOE* targeted-replacement mice were originally developed on a C57Bl/6 background to express human *APOE3* or *APOE4* genes, in place of the mouse *Apoe* gene, under the control of the endogenous murine promoter ([@awy289-B54]). Mice homozygous for either the human *APOE3* or the human *APOE4* genes are referred to in the text as *APOE3* and *APOE4* mice, respectively. Heterozygous mice expressing one copy of human *APOE3* and one copy of human *APOE4* are referred to as *APOE3*/*E4* mice. Mice were group housed under controlled temperature and lighting conditions with same-sex littermates and given free access to food and water. Mice were investigated at 6, 12, and 18 months of age as indicated. Approximately equal cohorts of males and females were examined; analysis of data by sex in this study did not reveal significant differences, and the results were pooled. Genotypes were confirmed by restriction fragment length polymorphism (RFLP) analysis following PCR, as previously described ([@awy289-B21]).

Human brain tissue preparation
------------------------------

Formalin-fixed and corresponding blocks of frozen (−80°C) post-mortem brain tissues from Brodmann area 9/10 of healthy controls with no neuropathological diagnoses were kindly provided by the Emory Alzheimer\'s Disease Research Center of the Center for Neurodegenerative Disease brain and tissue bank, under the direction of Dr Marla Gearing (see [Table 1](#awy289-T1){ref-type="table"} for genotype, age at death, post-mortem interval, and diagnosis). Genotypes were confirmed by RFLP analysis following PCR, as described previously ([@awy289-B21]; [@awy289-B18]). To confirm that amyloid-β was not present in the cases and region examined, two paraffin sections from each fixed block of brain tissue were stained with 1% thioflavin-S (Millipore Sigma) in parallel with sections from a patient with Alzheimer\'s disease as a positive control. On average \>10 thioflavin-S positive plaques sized at ∼30 μm in diameter were detected in the positive Alzheimer\'s disease control in a 1 mm field of view. In contrast, no plaques were detected in any brain tissues used in this study. Table 1*APOE3, APOE3*/*E4* and *APOE4* human brain samples used in this study***APOE* genotypeAge at death, yPost-mortem interval (h)Race/sexBraak StageNeuropathological diagnosisPrimarySecondary**E3/3747C/fIIControl-E3/3466.5C/f0Control-E3/3656C/fIIControl-E3/35710C/mIIControl-E3/37517C/mIControlCoronary artery diseaseE3/36519C/f0ControlMetastatic ovarian cancerE3/39815C/mIControl-E3/4906C/mIIControlCongestive heart failureE3/4523C/f0ControlDiffuse plaquesE3/4608AA/fIControl-E4/46417C/fIIControlCerebral amyloid angiopathyE4/4536.5AA/mIIControl-[^2]

Extracellular vesicles isolation from the brain extracellular space
-------------------------------------------------------------------

Extracellular vesicles from frozen human tissue as well as from frozen murine right hemibrains (without the cerebellum and olfactory bulbs) were isolated by serial centrifugation and purified on a sucrose gradient, as we have described previously in detail ([@awy289-B43], [@awy289-B44]). Human extracellular vesicles were simultaneously isolated from the brain of an *APOE4* carrier and an age-matched *APOE3* homozygous individual. Mouse extracellular vesicles were isolated simultaneously from *APOE3*, *APOE4* and *APOE3*/*E4* brain tissue in aged-matched cohorts. Briefly, minced tissue was treated with papain (20 units/ml; Worthington) in 3.5 ml Hibernate A (BrainBits) at 37°C for 15 min. The enzymatic papain reaction was stopped with 6.5 ml of cold Hibernate A supplemented with protease inhibitors. Samples were serially spun at 300*g* at 4°C for 10 min, then 2000*g* for 10 min, and finally 10 000g for 30 min to pellet and discard cell debris. Extracellular vesicles were pelleted by spinning the resulting supernatants at 100 000*g* for 1 h. Extracellular vesicle pellets were resuspended in phosphate-buffered saline (PBS) supplemented with protease inhibitors and purified through step-wise sucrose gradients, ranging from 2 M to 0.25 M sucrose, that were spun for 16 h at 4°C at 200 000*g*. Seven fractions (corresponding to fractions a--g in the text) were collected, starting from the top of the sucrose gradient. Extracellular vesicles were pelleted from these fractions by spinning at 100 000*g* for 1 h at 4°C after dilution in PBS. Pellets were resuspended in cold PBS supplemented with protease inhibitors and lysed with RIPA buffer supplemented with protease inhibitors prior to protein and western blot analyses ([@awy289-B43], [@awy289-B44]). Protein levels of each extracellular vesicle-containing sucrose fraction were quantified using a BCA (bicinchoninic acid) Protein Assay Kit (Thermo Fisher Scientific). Extracellular vesicle protein levels were normalized to the weight of the brain tissue from which the extracellular vesicles were isolated.

Electron microscopy
-------------------

Isolated extracellular vesicles were diluted 1/10 in 2% paraformaldehyde in 0.1 M sodium cacodylate buffer. Formvar covered carbon-coated copper 200-mesh grids were glow discharged in a Pelco easiGlow™. The extracellular vesicle-containing solution (3 μl) was added to a grid, held by self-clamping tweezers, and left for 20 s. The solution was then wicked off with Whatman™ filter paper and negatively stained using 5 μl of 1% uranyl acetate solution before being immediately wicked off using filter paper. This process was repeated three times before a final incubation of 5 min. The excess solution was wicked off and the grid allowed to air dry. Imaging took place on a Thermo Fisher Talos L120C transmission electron microscope operating at 120 kV.

Lipid analysis
--------------

Extracellular vesicle lipid analysis was done using fresh hemibrain tissue, which was otherwise prepared identically to frozen brain tissue. Extracellular vesicle-containing fractions and brain homogenates were lyophilized and resuspended in methyl tert-butyl ether/methanol (1:1). Samples were centrifuged at 500*g* for 5 min and the lipid-containing supernatant extracted. The resulting delipidated extracellular vesicle pellets were solubilized in RIPA buffer and set aside for western blot analysis. Additional methyl tert-butyl ether and water were added to the supernatant to make a mixture of methanol, methyl tert-butyl ether, and water (1:3:1) that was partitioned into water and organic phases ([@awy289-B33]). Gangliosides in the water phase were separated by high-performance thin-layer chromatography (HPTLC) using a solvent system, chloroform/methanol/0.2% CaCl~2~ (60:40:9), stained with an orcinol reagent, and the amount of each ganglioside was determined as described ([@awy289-B48]). The upper organic methyl tert-butyl ether phase was evaporated to dryness and separated into neutral and acidic lipids using DEAE Sephadex® columns ([@awy289-B30]). The neutral lipid fraction containing ceramide and cholesterol were applied on HPTLC plates and developed first with hexane/ethyl acetate/water/acetic acid (3:4:5:2) until the solvent front ascended to 4 cm from origin, and second with hexane/methyl tert-butyl ether/acetic acid (98:2:1) until 9 cm above origin. The plate was then stained with 0.0001% primuline (Millipore Sigma), the fluorescent lipid bands were scanned with the Gel Logic molecular imaging system, and the amounts of cholesterol and ceramide were determined as described previously ([@awy289-B48]).

Western blot analysis
---------------------

Western blot analysis of mouse tissue was performed on extracellular vesicle fractions from the right hemibrain and parallel homogenates prepared from the left hemibrain. Human tissue western blot analysis was performed on extracellular vesicle fractions and brain homogenates that were prepared from adjacent frozen blocks of tissue. There were no statistical differences in protein band intensities between delipidated samples and untreated samples in any of our analyses, and the data were pooled. Proteins were separated by electrophoresis with Criterion™ 4--20% Tris-HCl gel electrophoresis gels (Bio-Rad) and transferred onto PVDF (polyvinylidene difluoride) membranes (Millipore Sigma). Membranes were incubated with antibodies against the exosomal markers ALIX (1:500, Millipore Sigma \#ABC40), TSG101 (1:350, GeneTex Inc \#GTX70255), Rab35 (1:1000, Cell Signaling \#9690S), or β-actin (1:2500, Abcam \#ab8226) overnight, and horseradish peroxidase-coupled secondary antibodies for 1 h. The membranes were incubated in chemiluminescent fluid (Pierce) for 5 min, and chemiluminescence was visualized on reflection autoradiography film. Protein band density was quantified using ImageJ (NIH, Bethesda, MD) and normalized to brain tissue weight.

Quantification of mRNA levels
-----------------------------

Quantitative PCR was performed on left hemibrains of *APOE* mice with RNA purified using the miRNeasy mini kit (Qiagen). Subsequent validation was done for quality and quantity utilizing RNA 6000 Nano (Agilent). RNA was reverse transcribed using random hexamers as described previously ([@awy289-B19]). TaqMan™ qPCR primers (Life Technologies) were used with samples assayed on a real-time qPCR cycler (7900HT, Life Technologies) in 96-well optical plates with coverfilm as described previously ([@awy289-B19]). Standard curves and cycle threshold were generated using standards obtained from total mouse brain RNA. The ddCT method was used to determine relative gene level differences between *APOE3* and *APOE4* mice ([@awy289-B3]). Succinate dehydrogenase complex flavoprotein subunit A (*Sdha*, Mm01352360_m1) qPCR product was used as a control housekeeping gene. Negative controls consisted of the reaction mixture without input RNA and reaction mixture without SuperScript® III enzyme. *APOE3* and *APOE4* were compared with respect to the PCR product synthesis of *Tsg101* (Mm00649956_mH), *Pdcd6ip* (Mm00478041_m1) and *Rab35* (Mm01204416_m1) genes.

Statistical analysis
--------------------

Western blots were quantified using NIH ImageJ (<http://rsb.info.nih.gov>). Extracellular vesicle data from mice were analysed using a repeated measures 2 × 3 ANOVA (genotype × age). Two-tailed *t*-tests assuming equal variance were used to make *post hoc* pair-wise genotype comparisons. Throughout, results are expressed as the mean ± standard error of the mean (SEM). Statistically significant findings are indicated as shown: \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001. Dots indicate individual data points. The value of *n* represents the number of animals and is given in the main text. For qPCR, the product synthesis for each gene was modelled as a function of mouse genotype, using mixed effects models with random mouse effect to account for the correlation between repeated assays on the same mouse. The product synthesis of *Tsg101, Pdcd6ip*, and *Rab35* were normalized to the qPCR product of the housekeeping gene *Sdha*.

Data availability
-----------------

The authors confirm that the data supporting the findings of this study are available within the article and its [Supplementary material](#sup1){ref-type="supplementary-material"}.

Results
=======

Apolipoprotein E4 expression leads to lower brain exosome levels
----------------------------------------------------------------

To determine the effect of *APOE4* genotype on exosomes, we isolated extracellular vesicles from brains using serial centrifugations and sucrose gradients as described previously ([@awy289-B43], [@awy289-B44]). Electron microscopy was used to confirm that extracellular vesicles were only present at sucrose gradient densities ranging from 1.09 to 1.17 g/ml (fractions b--d) and that the isolated extracellular vesicles were consistent in size and morphology with exosomes ([Fig. 1](#awy289-F1){ref-type="fig"}) ([@awy289-B43]). There were no noticeable differences in extracellular vesicle size or morphology by electron microscopy when comparing the extracellular vesicle-containing fractions (fractions b--d) or when comparing extracellular vesicles isolated from *APOE3* homozygous, *APOE3*/*E4* heterozygous, and *APOE4* homozygous mice ([Fig. 1](#awy289-F1){ref-type="fig"}).

![**Electron microscopy shows appropriately sized and shaped extracellular vesicles isolated from the brains of *APOE* mice.** Wide field electron microscopy imaging shows extracellular vesicles isolated from the brains of 12-month-old *APOE3, APOE3*/*E4*, and *APOE4* mice. No obvious differences were observed in size or morphology among the genotypes and among the three extracellular vesicle-containing fractions b--d.](awy289f1){#awy289-F1}

Human brain tissue for extracellular vesicle isolation was from individuals with ages that ranged from 46 to 98 years of age ([Table 1](#awy289-T1){ref-type="table"}), with a mean age of 68.6 ± 6.18 years for *APOE3* homozygous individuals and 63.8 ± 6.92 years for *APOE4* carriers. Frontal cortices of *APOE4* carriers (either *APOE4* homozygous or *APOE3*/*E4* heterozygous) contained significantly lower levels of extracellular vesicles than those of non-carriers (*APOE3* homozygous) as determined by total extracellular vesicle protein levels pooled from fractions b--d normalized to brain tissue weight \[46.9 ± 9.0% of *APOE3* individuals; *n* = 7 *APOE3, n* = 5 *APOE4* carriers, *t*(10) = 3.26, *P =* 0.009; [Fig. 2](#awy289-F2){ref-type="fig"}A\]. Levels of flotillin-1, a lipid-raft protein present in all extracellular vesicle subtypes ([@awy289-B24]), were not significantly different in extracellular vesicles isolated from *APOE4* carriers compared with *APOE3* brains \[*n* = 3 for both genotypes, *t*(4) = 0.85, *P =* 0.45; [Fig. 2](#awy289-F2){ref-type="fig"}B and C\]. While brain extracellular vesicles isolated by our protocol are primarily exosomes, other extracellular vesicles such as microvesicles may co-purify ([@awy289-B11]). We therefore examined levels of the proteins ALIX and TSG101, exosome-specific ESCRT components that are commonly used as exosome markers, in our extracellular vesicle fractions to determine if *APOE4* expression specifically affects exosome levels ([Fig. 2](#awy289-F2){ref-type="fig"}B and C). Lower levels in fractions b--d normalized to brain tissue weight were revealed for both ALIX \[40.02 ± 12.2% of *APOE3* individuals; *n* = 4, *t*(6) = 2.99, *P =* 0.02\] and TSG101 \[52.8 ± 3.6% of *APOE3* individuals; *n* = 4, *t*(7) = 2.98, *P =* 0.02\] in *APOE4* carriers compared with *APOE3* by western blot analyses ([Fig. 2](#awy289-F2){ref-type="fig"}B and C). Thus, we show that exosome levels are reduced in *APOE4*-expressing human brains.

![**Brain exosome levels are lower in human *APOE4*-carriers compared with homozygous *APOE3* individuals.** (**A**) Extracellular vesicle protein levels from human brains normalized to brain tissue weight. (**B**) A representative western blot showing ALIX and TSG101 (exosomal proteins), and flotillin-1 (a lipid-raft enriched protein) in the extracellular vesicles. (**C**) Quantification of band intensities normalized to brain tissue weight is shown for levels of ALIX, TSG101, and flotillin-1. Data are expressed as the mean ± SEM of the ratios of *APOE4* carriers to *APOE3*. \**P \<* 0.05, \*\**P \<* 0.01.](awy289f2){#awy289-F2}

To determine that the observed effects on exosome levels are solely dependent on *APOE* genotype, we isolated brain extracellular vesicles from humanized *APOE* homozygous mice that do not develop tau or amyloid-β pathology ([@awy289-B54]; [@awy289-B55]). Data from sucrose gradient fractions b--d were pooled for all analyses. Repeated measures 2 × 3 ANOVA (genotype × age) revealed a main effect of genotype \[*F*(1,78) = 9.37, *P =* 0.003\], but not age independent of genotype \[*F*(2,78) = 0.19, *P =* 0.82\], on brain extracellular vesicle total protein levels. In agreement with our human findings, *post hoc t*-test analysis between groups showed lower extracellular vesicle protein levels in the right hemibrains of 12-month-old \[88.2 ± 2.1% of *APOE3* levels; *n =* 18, *t*(34) = 3.3, *P =* 0.002; [Fig. 3](#awy289-F3){ref-type="fig"}A\] and 18-month-old \[91.4 ± 1.5% of *APOE3* levels; *n* = 10 *APOE3, n* = 11 *APOE4, t*(19) = 3.14, *P* = 0.005; [Fig. 3](#awy289-F3){ref-type="fig"}A\] *APOE4* compared with age-matched *APOE3* mice. Six-month-old *APOE4* mice showed no difference in brain extracellular vesicle protein levels when compared with age-matched *APOE3* mice \[*n =* 13 *APOE3, n* = 14 *APOE4, t*(25) = 0.98, *P =* 0.33; [Fig. 3](#awy289-F3){ref-type="fig"}A\], indicating that the *APOE4* effect on brain extracellular vesicles is age-dependent. Levels of flotillin-1 were not found to differ by *APOE* genotype at any age by *t*-test analyses \[6-month-old *n* = 5, *t*(8) = 1.67, *P =* 0.13; 12-month-old *n* = 5, *t*(8) = 0.48, *P =* 0.64; 18-month-old *n* = 5, *t*(8) = 2.31, *P =* 0.18; [Fig. 3](#awy289-F3){ref-type="fig"}B and E\]. Exosome-specific markers were examined in extracellular vesicle fractions to confirm that brain exosome levels were specifically affected by *APOE4* expression ([Fig. 3](#awy289-F3){ref-type="fig"}B). Repeated measures 2 × 3 ANOVA (genotype × age) revealed a main effect by genotype with significant interaction with age for both ALIX \[genotype *F*(1,46) = 8.79, *P =* 0.004; interaction *F*(2,46) = 8.55, *P =* 0.0007\] and TSG101 \[genotype *F*(1,30) = 5.99, *P =* 0.02; interaction *F*(2,30) = 7.05, *P =* 0.003\]. *Post hoc t*-test analyses between groups revealed that ALIX and TSG101 levels in the brain extracellular vesicles of *APOE4* mice were lower at both 12 \[ALIX 59.7 ± 4.8% of *APOE3*; *n* = 12, *t*(22) = 3.89, *P =* 0.0007; TSG101 82.8 ± 4.8% of *APOE3*; *n* = 6, *t*(10) = 2.34, *P =* 0.04\] and 18 months of age \[ALIX 62.4 ± 8.6% of *APOE3*; *n* = 5, *t*(8) = 3.10, *P =* 0.02; TSG101 60.5 ± 6.6% of *APOE3*; *n* = 6, *t*(10) = 4.23, *P =* 0.002\] when normalized to brain tissue weight ([Fig. 3](#awy289-F3){ref-type="fig"}C and D). ALIX and TSG101 levels did not differ in the brain extracellular vesicles of 6-month-old *APOE4* compared with *APOE3* mice \[ALIX *n* = 9, *t*(16) = 1.58, *P =* 0.13; TSG101 *n* = 6, *t*(10) = 1.13, *P =* 0.29; [Fig. 3](#awy289-F3){ref-type="fig"}C and D\].

![**Brain exosome levels are lower in *APOE4* compared with *APOE3* mice in an age-dependent manner.** (**A**) Protein levels in sucrose gradient fractions b--d from each age group are shown for extracellular vesicles isolated from mouse hemibrains normalized to hemibrain weight. (**B**) ALIX, TSG101, and flotillin-1 were analysed by western blotting. Quantification of band intensities normalized to initial hemibrain weight are shown for levels of ALIX (**C**), TSG101 (**D**), and flotillin-1 (**E**)**.** Data are expressed as the mean ± SEM of the ratios of *APOE4* to *APOE3*. \**P \<* 0.05, \*\**P \<* 0.01.](awy289f3){#awy289-F3}

Given that our human *APOE4* findings are from both homozygous *APOE4* and heterozygous *APOE3*/*E4* individuals ([Fig. 2](#awy289-F2){ref-type="fig"}), we repeated a study of 12-month-old mice with the addition of heterozygous *APOE3*/*E4* mice ([Fig. 4](#awy289-F4){ref-type="fig"}). These additional data confirmed that 12-month-old *APOE4* compared with *APOE3* mice showed significantly lower extracellular vesicle levels of total protein \[86.6 ± 4.1% of *APOE3*; *n* = 10 *APOE3, n* = 8 *APOE4, t*(16) = 2.21, *P =* 0.04\], ALIX \[64.5 ± 14.9% of *APOE3*; *n* = 7 *APOE3, n* = 6 *APOE4, t*(11) = 2.59, *P =* 0.03\], and TSG101 \[68.1 ± 15.1% of *APOE3*; *n* = 6 *APOE3, n* = 5 *APOE4, t*(9) = 2.34, *P =* 0.04\] ([Fig. 4](#awy289-F4){ref-type="fig"}). In these groups, 12-month-old *APOE4* compared with *APOE3* mice additionally showed significantly lower extracellular vesicle levels of flotillin-1 \[70.0 ± 10.5% of *APOE3*; *n* = 7, *t*(12) = 2.56, *P =* 0.02\] ([Fig. 4](#awy289-F4){ref-type="fig"}B and E). Analysis of extracellular vesicles isolated from the brains of 12-month-old *APOE3*/*E4* compared with *APOE3* mice revealed significantly lower levels of ALIX \[58.1 ± 19.0% of *APOE3, n* = 7, *t*(12) = 2.18, *P =* 0.048\] ([Fig. 4](#awy289-F4){ref-type="fig"}B and C). Lower but not significant levels were also detected for total extracellular vesicle protein \[92.8 ± 4.1% of *APOE3*; *n* = 10, *t*(18) = 1.37, *P =* 0.19\], flotillin-1 \[71.0 ± 14.3% of *APOE3*; *n* = 7, *t*(12) = 1.91, *P =* 0.08\], and TSG101 \[73.7 ± 12.4% of *APOE3*; *n* = 6, *t*(10) = 2.12, *P =* 0.06\] in the brain extracellular vesicles of 12-month-old *APOE3*/*E4* compared with *APOE3* mice ([Fig. 4](#awy289-F4){ref-type="fig"}). That these exosome marker levels in 12-month-old *APOE3*/*E4* mice brains were either significantly lower than in age-matched *APOE3* mice, or intermediate between the levels found in age-matched *APOE3* and *APOE4* mice, suggests that 12 months is a critical age when mechanisms of exosomal production and release begin to decline in *APOE4* carriers and that this decline may be gene-dose sensitive. Altogether, our findings indicate that *APOE4* expression leads to lower exosome levels in the brains of both humans and *APOE* mice, with the mice data further suggesting that the effect is ageing-dependent.

![***APOE4*-driven effects on exosome levels are gene dose dependent in 12-month-old mice.** (**A**) Protein levels in sucrose gradient fractions b--d are shown for extracellular vesicles isolated from mouse hemibrains normalized to hemibrain weight. (**B**) ALIX, TSG101, and flotillin-1 were analysed by western blotting. Quantification of band intensities normalized to initial hemibrain weight are shown for levels of ALIX (**c**), TSG101 (**D**), and flotillin-1 (**E**). Data are expressed as the mean ± SEM of the ratios when compared with *APOE3*. \**P \<* 0.05.](awy289f4){#awy289-F4}

Exosomal formation and secretion are downregulated in aged *APOE4* compared with *APOE3* mouse brains
-----------------------------------------------------------------------------------------------------

To determine whether *APOE* genotype-mediated differences in brain exosome levels are due to altered exosome biogenesis and/or secretion, we examined the expression of intraluminal vesicle formation regulators (ALIX and TSG101) as well as a regulator of multivesicular body fusion with the plasma membrane (Rab35) ([@awy289-B45]; [@awy289-B22]) in the brains of *APOE* mice ([Fig. 5](#awy289-F5){ref-type="fig"}). From the same mice in which extracellular vesicles were isolated from the right hemibrain, left hemibrain homogenates were used to measure protein expression levels of ALIX, TSG101, and Rab35. Repeated measures ANOVA (genotype × age) on hemibrain protein levels revealed a main effect of genotype for TSG101 \[*F*(1,50) = 14.14, *P =* 0.0004\], as well as of genotype and age with significant interaction for Rab35 \[genotype *F*(1,64) = 5.32, *P =* 0.02; age *F*(2,64) = 4.88, *P =* 0.01; interaction *F*(2,64) = 4.86, *P =* 0.01\]. *Post hoc t*-tests between groups revealed that TSG101 levels were reduced in *APOE4* compared with *APOE3* mice at 12 \[73.4 ± 8.4% of *APOE3*; *n* = 11 *APOE3, n* = 12 *APOE4, t*(21) = 2.44, *P =* 0.02\] and 18 months of age \[76.6 ± 5.8% of *APOE3*; *n* = 14 *APOE3, n* = 13 *APOE4, t*(25) = 3.16, *P =* 0.004; [Fig 5](#awy289-F5){ref-type="fig"}C\]. Rab35 levels in *APOE4* mice were significantly lower at 18 months of age \[67.4 ± 4.7% of *APOE3*; *n* = 14 *APOE3, n* = 13 *APOE4, t*(25) = 4.83, *P =* 0.00006; [Fig. 5](#awy289-F5){ref-type="fig"}D\]. Consistent with the lack of exosome level differences at 6 months of age, hemibrain levels of TSG101 and Rab35 showed no significant genotype-mediated differences at this age \[TSG101 *n* = 5, *t*(8) = 1.28, *P =* 0.24; Rab35 *n* = 7; *t*(12) = 0.35, *P =* 0.74; [Fig. 5](#awy289-F5){ref-type="fig"}C and D\]. ALIX levels were not significantly different in the hemibrains of *APOE4* mice compared with *APOE3* mice at any age \[6 months old *n* = 7, *t*(12) = 0.09, *P =* 0.93; 12 months old *n* = 13 *APOE3, n* = 14 *APOE4, t*(25) = 1.28, *P =* 0.21; 18 months old *n* = 16 *APOE3, n* = 15 *APOE4, t*(29) = 1.46, *P =* 0.16; [Fig 5](#awy289-F5){ref-type="fig"}B\]. To determine if *APOE4*-mediated reductions in protein levels were due to downregulated transcription, we conducted qPCR analyses for *Pdcd6ip* (encodes ALIX), *Tsg101*, and *Rab35* mRNA from the hemibrains of 12-month-old *APOE* mice. Brain mRNA levels were reduced for *Tsg101* \[88.8 ± 1.9% of *APOE3*; *n* = 6, *t*(23) = 4.05, *P =* 0.0005\] and *Rab35* \[87.3 ± 2.2% of *APOE3*; *n* = 6, *t*(25) = 4.24, *P =* 0.0003\] in *APOE4* compared with *APOE3* mice, whereas *Pdcd6ip* mRNA levels were not statistically different \[91.0 ± 4.1% of *APOE3*; *n* = 6, *t*(24) = 1.60, *P =* 0.12; [Fig. 5](#awy289-F5){ref-type="fig"}E\]. Altogether, our findings suggest that a downregulation of molecular events involved in exosomal biogenesis and secretion lead to the reduction of brain exosome levels in *APOE4* carriers.

![**Expression levels of TSG101 and Rab35 are lower in aged *APOE4* mouse brains compared with age-matched *APOE3* mice.** (**A**) Representative western blot analyses of mouse hemibrain homogenates are shown for ALIX, TSG101, and Rab35, with β-actin used as a loading control. (**B**--**D**) Quantification of bands normalized to levels of β-actin is shown for levels of ALIX (**B**)**,** TSG101 (**C**), and Rab35 (**D**)**.** (**E**) Quantitative PCR analysis of 12-month-old mouse hemibrains shows *Pdcd6ip* (encodes ALIX), *Tsg101*, and *Rab35* transcript levels normalized to ddCT levels of the housekeeping gene *Sdha*. Data are expressed as the mean ± SEM of the ratios of *APOE4* to *APOE3*. \**P \<* 0.05, \*\**P \<* 0.01, \*\*\**P \<* 0.001.](awy289f5){#awy289-F5}

Lipid composition is altered in *APOE4* mice exosomes
-----------------------------------------------------

Lipids such as cholesterol, ceramides, and gangliosides are enriched in exosomal membranes when compared with other cell membranes, reflecting the unique lipid environment of multivesicular bodies ([@awy289-B35]). We determined the concentrations of cholesterol, ceramide, and gangliosides in 12-month-old *APOE* mouse brains and brain extracellular vesicles. As previously reported ([@awy289-B35]), our mouse brain extracellular vesicles were ∼10 times as enriched in cholesterol and ∼50 times as enriched in ceramide and gangliosides compared with total brain lipid concentrations ([Fig. 6](#awy289-F6){ref-type="fig"}). At the hemibrain level, cholesterol concentrations were higher in 12-month-old *APOE4* compared with age-matched *APOE3* mouse brains \[112.6 ± 3.9% of *APOE3; n* = 4 *APOE3, n* = 5 *APOE4, t*(7) = 2.59, *P* = 0.04; [Fig. 6](#awy289-F6){ref-type="fig"}A\], while concentrations of ceramide and gangliosides did not differ ([Fig. 6](#awy289-F6){ref-type="fig"}B and C). Cholesterol concentrations were also higher in the brain extracellular vesicles of *APOE4* compared with *APOE3* mice \[115.0 ± 5.9% of *APOE3; n* = 5, *t*(8) = 3.38, *P* = 0.01; [Fig. 6](#awy289-F6){ref-type="fig"}A\]. Consistent with previous observations that endosomal cholesterol build-up is commonly associated with ganglioside accumulation ([@awy289-B29]), *APOE4* mouse brain extracellular vesicles had higher levels of the ganglioside-precursor ceramide \[116 ± 4.5% of *APOE3; n* = 5, *t*(8) = 3.36, *P* = 0.01; [Fig. 6](#awy289-F6){ref-type="fig"}B\] as well as the ganglioside GD1a \[125.2 ± 6.3% of *APOE3; n* = 3; *t*(4) = 3.97, *P* = 0.02, [Fig. 6](#awy289-F6){ref-type="fig"}C\]. These findings demonstrate that *APOE4* alters brain and extracellular vesicle cholesterol levels, with associated changes in extracellular vesicle levels of ceramide and ganglioside.

![**Differences in brain extracellular vesicle lipids in *APOE4* compared with *APOE3* mice.** Brain and extracellular vesicle lipid concentrations are given in μg/mg of protein for (**A**) cholesterol, (**B**) ceramide, and (**C**) gangliosides. Data are expressed as the mean ± SEM. \**P \<* 0.05, \*\**P \<* 0.01.](awy289f6){#awy289-F6}

Discussion
==========

Our findings demonstrate an *APOE4*-mediated decrease in brain exosome levels in both humans and humanized *APOE* mice, with our mouse findings showing that this is ageing-dependent, consistent with *APOE4*\'s contribution to ageing-related disease risk ([@awy289-B31]). Our findings further indicate that exosomal decrease follows a downregulation of exosome biogenesis and secretion from the endosomal pathway. We reveal a transcriptional and protein level downregulation of TSG101 in the brains of aged *APOE4* mice, consistent with previous findings that depleting specific ESCRT components such as TSG101 is sufficient to decrease exosome secretion *in vitro* ([@awy289-B13]). While we did not find a reduction in the brain expression of ALIX, an ESCRT-associated protein that interacts with TSG101 during intraluminal vesical formation, this finding agrees with data from depletion studies suggesting that ALIX\'s contribution to exosome formation may depend on the cell type ([@awy289-B5]; [@awy289-B13]). The observed reduction in exosome secretion is additionally supported by our finding that *APOE4* downregulates Rab35, a rab GTPase that functions in the docking of multivesicular bodies to the plasma membrane for exosome release. Inhibition of Rab35 has been shown to lead to impaired exosome secretion in several *in vitro* models ([@awy289-B22]; [@awy289-B1]). Taken together, our data indicate that lower exosome levels in the brains of *APOE4* carriers are likely a consequence of downregulated exosome biogenesis and secretion rather than changes in exosome stability or clearance from the brain extracellular space.

The apolipoprotein E protein is likely to exert its effects on endosomal and exosomal pathways through its primary role as a lipid carrier, supported by studies that *APOE4* compared with *APOE3* expression disrupts neuronal and peripheral cholesterol metabolism ([@awy289-B52]; [@awy289-B34]). We found an increase in cholesterol levels in the exosomes of *APOE4* compared with *APOE3* mice that likely reflects altered lipid metabolism within the endosomal pathway from which they originate. Lipids such as cholesterol accumulate in intracellular vesicles under certain pathological conditions, such as in Alzheimer\'s disease and select lysosomal storage disorders ([@awy289-B15]; [@awy289-B25]). Aberrant accumulation of cholesterol, along with the secondary accumulation of sphingolipids, can cause disturbances in the endosomal pathway that affect both the morphology and motility of endosomal compartments ([@awy289-B26]; [@awy289-B32]). For example, endosomal cholesterol accumulation has been shown to immobilize multivesicular bodies through the impaired inactivation of Rab7 ([@awy289-B26]; [@awy289-B9]). We therefore suggest that *APOE4*\'s disruption of intracellular cholesterol metabolism may be directly associated with compromised exosome production. While several other members of the Rab protein family are known to be regulated by endosomal cholesterol levels ([@awy289-B10]; [@awy289-B20]), it remains to be determined if Rab35 function, which shows decreased levels in brains of *APOE4* mice, may also be affected by changes in cholesterol levels.

An *APOE4-*mediated alteration in brain exosome pathways introduces an additional component to the endosomal-lysosomal disruption that appears to be a prominent feature of *APOE4*-driven neuronal changes ([@awy289-B8]; [@awy289-B39]; [@awy289-B58]). Alzheimer\'s disease-related early endosome enlargement in neurons was previously shown by [@awy289-B8] to be more prominent in *APOE4* carriers than non-carriers, including in brain regions not affected by amyloid-β pathology. More recently, 22-month-old *APOE4* mice were found to have neuronal endosomal pathology that impairs insulin signalling ([@awy289-B58]). Moreover, we have recently demonstrated with RNA sequencing that carrying an *APOE4* allele leads to robust alterations in the expression of multiples genes involved in the endosomal-lysosomal system when comparing the Alzheimer\'s disease-vulnerable entorhinal cortex to an Alzheimer\'s disease-resistant brain region (primary visual cortex) of 14 to 15-month-old *APOE* mice ([@awy289-B39]). We additionally showed that the number and size of early endosomes is increased in cingulate cortex pyramidal neurons of *APOE4* mice at 18 months of age, but not at 12 months or earlier ages ([@awy289-B39]). Further evidence for *APOE4-*dependent lysosomal changes comes from our findings that lysosome number is increased in the entorhinal pyramidal neurons of 18-month-old *APOE4* mice ([@awy289-B39]). The current findings show that *APOE4*-driven brain exosome compromise at 12 months of age occurs earlier than the reported *APOE4*-driven endosome or lysosome changes, raising the possibility that reduced outward flux through the exosomal pathway might contribute to subsequent endosomal-lysosomal pathway alterations. Down syndrome patients and mouse models of the disease all show early endosome enlargement (Colacurcio *et al.*, 2017), which is also associated with a change in the exosomal pathway, albeit an increase in exosome production ([@awy289-B17]). Importantly in this study, reducing exosome generation worsened the endosomal pathology in cultured Down syndrome fibroblasts ([@awy289-B17]), suggesting that flux through the exosomal pathway is an important regulator of endosomal compartments. Similarly, knockdown of TSG101 and Rab35 in cells *in vitro* has been shown to result in morphological endosomal changes in addition to downregulating exosome secretion ([@awy289-B47]; [@awy289-B2]). Thus, reduced exosome release in *APOE4* carriers may be a contributing factor to the extensive neuronal endosomal pathway alterations that have been linked to this allele.

Our findings link the *APOE4* genotype to a failure in brain exosome production in an *in vivo*, Alzheimer\'s disease pathology-free setting, contributing to existing evidence that the neuronal endosomal-lysosomal system is broadly disrupted in individuals expressing this allele. Disturbances of endosomal-lysosomal system function often result in the accumulation of surplus material in neuronal endosomes and lysosomes ([@awy289-B36]), and disruptions throughout these pathways are an important factor contributing to neuronal vulnerability in numerous neurodegenerative disorders, including Alzheimer\'s disease ([@awy289-B37]; [@awy289-B49]). Consistent with our findings here, we propose that endosomal material released into the extracellular space via exosomes is an important mechanism by which neurons remove debris, and that failure of efficient exosome production and release can exacerbate and perhaps lead to endosomal pathway disturbances ([@awy289-B17]). This failure to maintain proper functioning of the neuronal endosomal-lysosomal and exosomal pathways in *APOE4* carriers during ageing may not only disturb essential homeostatic and catabolic cellular processes, but may also contribute to neuronal vulnerability and the risk of developing neurodegenerative disorders such as Alzheimer\'s disease ([@awy289-B38]).
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ALIX

:   apoptosis-linked gene 2-interacting protein X
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:   endosomal sorting complexes required for transport
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